Prognostic Factors in Non-Small Cell Lung Cancer

94.1K

views

282

authors

37

articles

Prognostic Factors in Non-Small Cell Lung Cancer

94.1K

views

282

authors

37

articles

Editorial

14 March 2023

Editorial: Prognostic factors in non-small cell lung cancer

Mohamed Rahouma

,

Massimo Baudo

,

Jun Zhang

and

Luciano Mutti

712 views

0 citations

Editors

3

University of L'Aquila

University of Kansas Medical Center

Mohamed Rahouma, MD, PhD, MSc, MS

Weill Cornell Medical Center, NewYork-Presbyterian

Impact

Fetching...

About

Lung cancer is a leading cause of cancer-related death worldwide. In 2008, the number of incident cases was estimated to be around 1.6 million (13% of all incident cancers). Accounting for approximately 85% of all cases, non-small-cell lung carcinoma (NSCLC) is the most common type of lung cancer. Due to high rates of metastasis, recurrence, and drug resistance the prognosis for NSCLC remains low despite advances in treatment such as targeted and immunotherapy.

The staging of cancer is one of the most reproducible prognostic factors with the TNM classification based on tumor size (T), nodal (N) and metastatic (M) involvement. However, this does not take the tumor molecular and immune characteristics into account. There has been an increasing number of studies on biological markers that are not routinely measured in clinical practice. Often, these factors are not reproducible and their prognostic independent value is not proven, with adjustment for well-known prognostic factors. Therefore, it is vital to identify further prognostic biomarkers that can be detected at the early stage of the disease and can serve as potential treatment targets.

In this Research Topic we welcome studies that focus on, but are not limited to:

- Prognostic value of tumor metabolic activity in NSCLC
- Prognostic gene signatures in NSCLC
- Long non-coding RNAs as prognostic biomarkers in NSCLC
- Immune-Related Prognostic Biomarkers in NSCLC

Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.

Lung cancer is a leading cause of cancer-related death worldwide. In 2008, the number of incident cases was estimated to be around 1.6 million (13% of all incident cancers). Accounting for approximately 85% of all cases, non-small-cell lung carcinoma (NSCLC) is the most common type of lung cancer. Due to high rates of metastasis, recurrence, and drug resistance the prognosis for NSCLC remains low despite advances in treatment such as targeted and immunotherapy.

The staging of cancer is one of the most reproducible prognostic factors with the TNM classification based on tumor size (T), nodal (N) and metastatic (M) involvement. However, this does not take the tumor molecular and immune characteristics into account. There has been an increasing number of studies on biological markers that are not routinely measured in clinical practice. Often, these factors are not reproducible and their prognostic independent value is not proven, with adjustment for well-known prognostic factors. Therefore, it is vital to identify further prognostic biomarkers that can be detected at the early stage of the disease and can serve as potential treatment targets.

In this Research Topic we welcome studies that focus on, but are not limited to:

- Prognostic value of tumor metabolic activity in NSCLC
- Prognostic gene signatures in NSCLC
- Long non-coding RNAs as prognostic biomarkers in NSCLC
- Immune-Related Prognostic Biomarkers in NSCLC

Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.

Download ebook

Share

Editors

University of L'Aquila

University of Kansas Medical Center

Mohamed Rahouma, MD, PhD, MSc, MS

Weill Cornell Medical Center, NewYork-Presbyterian

Impact

94,060 Total views

57,977 Article views

34,951 Article downloads

1,132 Topic views

Published In

Journal Thumbnail

Frontiers in Oncology

Thoracic Oncology

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic